Alameda, CA, United States of America

Kenneth Flanagan

USPTO Granted Patents = 9 

 

Average Co-Inventor Count = 3.5

ph-index = 3

Forward Citations = 37(Granted Patents)


Location History:

  • San Francisco, CA (US) (2011 - 2016)
  • Alameda, CA (US) (2018 - 2021)

Company Filing History:


Years Active: 2011-2021

Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Kenneth Flanagan

Introduction

Kenneth Flanagan is a notable inventor based in Alameda, California, with a remarkable portfolio of nine patents. His work primarily focuses on the development of antibodies that have significant implications in cancer detection and treatment.

Latest Patents

Flanagan's latest patents include the invention of Anti-Laminin4 antibodies specific for LG4-5. This invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin α4. These antibodies can preferentially stain cancer or tumor cells or tissue. They are designed for various applications, including detecting cancer, evaluating the efficacy of cancer therapies, treating cancer, and addressing obesity or obesity-related diseases.

Career Highlights

Throughout his career, Kenneth Flanagan has made significant contributions to the field of biotechnology. He has worked with prominent companies such as Prothena Biosciences Limited and Genentech, Inc., where he has applied his expertise in developing innovative solutions for complex medical challenges.

Collaborations

Flanagan has collaborated with esteemed colleagues, including Theodore A. Yednock and Jeanne E. Baker, further enhancing the impact of his work in the scientific community.

Conclusion

Kenneth Flanagan's innovative contributions to the field of biotechnology, particularly in cancer research, highlight his role as a leading inventor. His patents and collaborations continue to influence advancements in medical science and treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…